The FDA has awarded 510(k) clearance for GE Healthcare’s new imaging technology for liver embolization. The new imaging technology is branded as FlightPlan for Liver. According to a press release by the company, FlightPlan for Liver has been on the public market in Asia, Europe and Latin America for at least one year.
According to the company, the new imaging technology is beneficial during liver embolization interventions. By providing a 3D roadmap of a patient’s vessels, it’s possible for a surgeon to deliver a catheter to the site of a lesion with a high degree of precision. In the past, it has been very difficult for surgeons to identify the individual blood vessels that feed a liver tumor. In addition, many existing treatment solutions require lots of contrast media and moderate use of radiation-emitting tools. With the new GE technology, the process of preparing a liver embolization is significantly simpler.
Chantal Le Chat is the general manager of detection and guidance solutions at GE Health. In a prepared remark, he stated, "With FlightPlan for Liver, interventionalists can gain confidence in identifying tumor-feeding vessels and be more selective when planning liver embolization.”